Phesgo and Alcohol/Food Interactions
There are 2 alcohol/food/lifestyle interactions with Phesgo (hyaluronidase / pertuzumab / trastuzumab).
Trastuzumab High Blood Pressure (Hypertension)
Moderate Potential Hazard, Moderate plausibility
HER2 inhibitors - CHF
Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity. Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF. Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions. Evaluate cardiac function before, during, and upon completion of treatment. Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further. It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.
References (5)
- (2001) "Product Information. Herceptin (trastuzumab)." Genentech
- (2007) "Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals
- (2012) "Product Information. Perjeta (pertuzumab)." Genentech
- (2022) "Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech
- (2021) "Product Information. Margenza (margetuximab)." Almirall
Pertuzumab High Blood Pressure (Hypertension)
Moderate Potential Hazard, Moderate plausibility
HER2 inhibitors - CHF
Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity. Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF. Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions. Evaluate cardiac function before, during, and upon completion of treatment. Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further. It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.
References (5)
- (2001) "Product Information. Herceptin (trastuzumab)." Genentech
- (2007) "Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals
- (2012) "Product Information. Perjeta (pertuzumab)." Genentech
- (2022) "Product Information. Kadcyla (ado-trastuzumab emtansine)." Genentech
- (2021) "Product Information. Margenza (margetuximab)." Almirall
Switch to consumer interaction data
Phesgo drug interactions
There are 275 drug interactions with Phesgo (hyaluronidase / pertuzumab / trastuzumab).
Phesgo disease interactions
There are 5 disease interactions with Phesgo (hyaluronidase / pertuzumab / trastuzumab) which include:
Report options
More about Phesgo (hyaluronidase / pertuzumab / trastuzumab)
- Phesgo consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: HER2 inhibitors
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Arimidex
Arimidex is used to treat breast cancer in postmenopausal women. Learn about side effects ...
Femara
Femara lowers estrogen levels and is used to treat breast cancer in postmenopausal women. Learn ...
Xeloda
Xeloda is used to treat breast and colorectal cancers. Learn about side effects, interactions and ...
Herceptin
Herceptin is used to treat patients with metastatic breast cancer. Learn about side effects ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
